Advanced search
Publication Cover
Hematology Volume 28, 2023 - Issue 1
Submit an article Journal homepage
1,075
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Outcomes of adult patients with type 1 primary refractory acute myeloid leukemia: a single center experience

Zhiyou Yua National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of ChinaView further author information
,
Yao Yaoa National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of ChinaView further author information
,
Yanming Zhangb Department of Hematology, The Affiliated Huai'an Hospital of Xuzhou Medical University and The Second People's Hospital of Huai'an, Huai'an, People’s Republic of ChinaView further author information
,
Jia Chena National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China;c Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, People’s Republic of ChinaView further author information
,
Yang Xua National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China;c Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, People’s Republic of China;d Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, People’s Republic of ChinaView further author information
,
Shengli Xuea National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China;c Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, People’s Republic of ChinaView further author information
,
Huiying Qiua National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China;c Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, People’s Republic of ChinaView further author information
,
Xiaowen Tanga National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China;c Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, People’s Republic of China;d Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, People’s Republic of ChinaView further author information
,
Yue Hana National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China;c Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, People’s Republic of China;d Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, People’s Republic of ChinaView further author information
,
Suning Chena National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China;c Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, People’s Republic of China;d Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, People’s Republic of ChinaView further author information
,
Aining Suna National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China;c Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, People’s Republic of ChinaView further author information
,
Depei Wua National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China;c Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, People’s Republic of China;d Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, People’s Republic of China;e State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, People’s Republic of ChinaCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0002-6312-3863View further author information
ORCID Icon &
Ying Wanga National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China;c Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, People’s Republic of China;d Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, People’s Republic of ChinaCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0002-8015-3546View further author information
ORCID Icon show all
Article: 2212534 | Received 18 Feb 2023, Accepted 07 May 2023, Published online: 16 May 2023

Figures & data

Figure 1. Flow diagram of the patients.

Figure 1. Flow diagram of the patients.

Table 1. Patient characteristics.

Figure 2. Kaplan–Meier curves for overall survival. (a) The whole cohort. (b) ID/HD Ara-C based intensive chemotherapy group vs. G-CSF primed less intensive chemotherapy group. (c) ID/HD Ara-C based intensive chemotherapy group vs. G-CSF primed less intensive chemotherapy group, censored at time of allo-HSCT. (d) Patients who received allo-HSCT vs. those not.

Figure 2. Kaplan–Meier curves for overall survival. (a) The whole cohort. (b) ID/HD Ara-C based intensive chemotherapy group vs. G-CSF primed less intensive chemotherapy group. (c) ID/HD Ara-C based intensive chemotherapy group vs. G-CSF primed less intensive chemotherapy group, censored at time of allo-HSCT. (d) Patients who received allo-HSCT vs. those not.

Figure 3. Kaplan–Meier curves for overall survival of the 42 patients underwent allo-HSCT according to (a) reinduction regimen and (b) disease status after salvage treatment.

Figure 3. Kaplan–Meier curves for overall survival of the 42 patients underwent allo-HSCT according to (a) reinduction regimen and (b) disease status after salvage treatment.

Table 2. Univariate and multivariate analysis of clinical parameters on overall survival.

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.